

FORM 51 – 102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company

bioMmune Technologies Inc.
1780 – 400 Burrard Street
Vancouver, BC V6C 3A6

2. Date of Material Change

September 20, 2016

3. News Release

A news release dated September 20, 2016 was disseminated through Marketwired and was filed via SEDAR the same day.

4. Summary of the Material Change

bioMmune Technologies Inc. appoints Thomas Gadek, Ph.D. to its board of directors.

5. Full Description of the Material Change

bioMmune Technologies Inc. (“bioMmune” or the “Company”) (TSX.V: IMU), a drug discovery and development biotechnology company, today announced the appointment of Dr. Thomas R. Gadek to its Board of Directors.

“Tom’s demonstrated success as a discovery scientist and his experience of executive leadership is a perfect fit for our board,” said Patrick Gray, CEO of bioMmune. “We are very pleased to welcome Tom, as his expertise will greatly aid our ability to discover and develop life-saving therapeutics and also create significant value for our shareholders”.

Dr. Gadek has had an illustrious career in the biotechnology industry spanning 33 years. He has discovered and developed novel, first in class molecules addressing emerging protein therapeutic targets. These efforts have been chronicled as an author on 54 peer reviewed publications, and as an inventor on 64 issued and 76 pending United States patents. Dr. Gadek initially gained experience and expertise at larger companies, 5 years at Syntax and 15 years at Genentech. He then founded the venture backed startup SARcode, where he was CEO and Board member. Dr. Gadek engineered the target identification, lead discovery, and clinical proof of concept for the development of Lifitegrast, a treatment for dry eye. This resulted in the acquisition of SARcode by Shire, and the approval of Lifitegrast by the FDA in 2016. Throughout his career, Dr. Gadek has gained experience in all aspects of modern drug discovery and development. His expertise covers the realm of immunology and inflammation, particularly in the fields of ophthalmology and dermatology. As a renowned medicinal chemist, he has pioneered the understanding of the transfer of protein epitopes to small molecule scaffolds for the identification of inhibitors of protein-protein interactions. Dr. Gadek

obtained his Ph.D. in Chemistry from the University of California, Berkeley following a Bachelors degree from the University of Colorado and a Masters degree from MIT.

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102

N/A

7. Omitted Information

N/A

8. Executive Officer

Dr. Reinhard Gabathuler, President
Phone: (514) 963-6177

9. Date of Report

September 28, 2016